Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J O'Byrne, Denis Moro-Sibilot, D Ross Camidge, Tony Mok, Vera Hirsh, Gregory J Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D Wilner, Pasi A Jänne
BACKGROUND: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown. METHODS: We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen...
June 20, 2013: New England Journal of Medicine